Arteris, INC Form 4 insider transactions

Director Raman Chitkara was granted 4,703 restricted stock units as part of his compensation for service to Arteris, Inc.

Director Wayne Cantwell acquired 7,839 restricted stock units in Arteris, Inc. as part of an equity compensation grant.

Director S. Atiq Raza reported a grant of restricted stock units and the subsequent sale of shares held in a family trust.

Arteris, Inc. VP and General Counsel Paul Alpern exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Director Saiyed Atiq Raza of Arteris, Inc. has reported the sale of common stock valued at approximately $2.39 million through a pre-arranged trading plan.

Arteris, Inc. CFO Nicholas Hawkins sold 3,000 shares of common stock at an average price of $37.75 per share.

Arteris, Inc. Director Wayne C. Cantwell sold 38,500 shares of common stock at a weighted average price of $37.2251.

Arteris, Inc. CEO Charles Janac reported a gift of 50,000 shares of common stock from a family-controlled entity.

Bayview Legacy, LLC reported a gift transfer of 50,000 shares of Arteris, Inc. common stock.

Arteris, Inc. CFO Nicholas Hawkins exercised stock options and sold a portion of the resulting shares on May 15, 2026.

Director Antonio J. Viana sold 40,000 shares of Arteris, Inc. common stock via a pre-arranged 10b5-1 trading plan.

Arteris, Inc. President and CEO, Janac K Charles, sold 70,000 shares of common stock for approximately $31.20 per share as part of a pre-arranged trading plan.

Bayview Legacy, LLC, managed by K. Charles Janac, reported the sale of 70,000 shares of Arteris, Inc. common stock for approximately $31.20 per share under a pre-established 10b5-1 trading plan.

Arteris, Inc. Director Antonio J. Viana sold 20,000 shares of common stock via a pre-arranged 10b5-1 trading plan.

Arteris, Inc. Director Raman Chitkara sold 5,000 shares of common stock on May 5, 2026, via a pre-arranged 10b5-1 trading plan.

Director Saiyed Atiq Raza of Arteris, Inc. has sold a significant number of shares as part of a pre-established trading plan.

Arteris, Inc. Director Raman Chitkara reported a sale of 5,000 shares of common stock for $25.0579 per share, executed under a pre-established 10b5-1 trading plan.

Arteris, Inc. Director Antonio J. Viana reported the sale of 20,000 shares of common stock for $26.11 per share, executed under a pre-established 10b5-1 trading plan.

Arteris, Inc. Director Saiyed Atiq Raza has reported the sale of company stock valued at over $1.5 million through a pre-arranged trading plan.

Arteris, Inc. Director Antonio J. Viana reported a sale of 20,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Arteris, Inc. Chief Operating Officer Laurent Moll sold 13,448 shares of common stock via a pre-arranged 10b5-1 trading plan.

Arteris, Inc. Director Raman Chitkara sold 5,000 shares of common stock at a weighted average price of $20.05 per share.

Arteris Inc. Chief Operating Officer Moll Laurent R reported the sale of common stock under a pre-arranged 10b5-1 trading plan.

Arteris, Inc. (AIP) reports a Form 4 filing detailing the sale of common stock by President and CEO K. Charles Janac, executed under a pre-established 10b5-1 trading plan.

Bayview Legacy, LLC, controlled by K. Charles Janac, reported the sale of 70,000 shares of Arteris, Inc. common stock for approximately $19.04 per share, executed under a pre-arranged 10b5-1 trading plan.

Arteris, Inc. Director Joachim Kunkel acquired 899 shares of common stock as retainer fees, valued at $15.98 per share.

Arteris, Inc. Director Claudia F. Munce acquired 860 shares of common stock as fully vested restricted stock, representing retainer fees elected in lieu of cash.

Arteris Inc. VP and CFO Nicholas B. Hawkins sold company stock to cover tax liabilities from restricted stock unit releases.

Arteris, Inc. Chief Operating Officer Moll Laurent R has reported the sale of company shares to cover tax obligations and transactions made under a pre-arranged trading plan.

Arteris Inc. President and CEO K. Charles Janac reported the sale of common stock to cover tax liabilities related to restricted stock unit releases, with some transactions executed under a 10b5-1 plan.